Search for tag: "pd-l1 (sp142)"

Case Study: Assessing PD-L1 in TNBC - Select cases with staining near the scoring algorithm cut-off

Dr. Michael Lynch of Medical and Scientific Affairs for Roche Diagnostics reviews 3 cases that show the borderline tissue staining of IC around 1% of tumor area that a pathologist will see in the…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 4 plays

Case Study: Assessing PD-L1 in TNBC - Scoring cases with common staining patterns

Dr. Michael Lynch of Medical and Scientific Affairs for Roche Diagnostics reviews 3 cases that show the most common pattern of tissue staining a pathologist will see in the triple negative breast…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 3 plays

Case Study: Assessing PD-L1 in TNBC. Moderate IC staining without TC staining

Dr. Michael Lynch of Medical and Scientific Affairs for Roche Diagnostics reviews 3 cases that show the most common tissue staining pattern a pathologist will see in the triple negative breast cancer…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 4 plays

PD-L1 testing and SP142 assay as a diagnostic tool in triple negative breast cancer (TNBC)

VENTANA PD-L1 (SP142) assay is the first and only FDA-approved assay for mTNBC*. Testing for PD-L1 identifies patients who could benefit from TECENTRIQ + nab-pac in 1L mTNBC** This video is…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 5 plays

VENTANA PD-L1 (SP142) Assay

VENTANA PD-L1 (SP142) IHC assay is FDA-approved for mTNBC. Test for PD-L1 to identify patients who could benefit from TECENTRIQ + nab-pac in 1L mTNBC* This video is intended for US healthcare…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 7 plays

PD-L1 Testing and SP142 IHC Assay as a Diagnostic Tool in Urothelial Carcinoma

US Pathologist, Dr. Michael Lynch, from the Medical and Scientific Affairs (MSA) department for Roche Tissue Diagnostics discusses: 1. SP142 assay is optimized for staining for both immune and…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 9 plays

PD-L1 Testing and Developmental Process for Companion Diagnostic Tests

US Pathologist, Dr. Michael Lynch, from the Medical and Scientific Affairs (MSA) department for Roche Tissue Diagnostics discusses on: 1. The PD-L1 biomarker and its role in immunotherapy - time…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 12 plays

PD-L1 Expression on Immune and Tumor Cells

US Pathologist, Dr. Michael Lynch, from the Medical and Scientific Affairs (MSA) department for Roche Tissue Diagnostics discusses: 1. How and why PD-L1 is present on tumor cells as well as being…

From  Bharathi Vennapusa on November 22nd, 2020 0 likes 12 plays

Changing Landscape of PD-L1-high NSCLC treatments

Changing landscape for PD-L1-high NSCLC treatmentsSpeakers: Dr Ross Soo (Singapore, Moderator), Dr Mark Socinski (US, Speaker), Dr Roy Herbst (US, Speaker), Dr Yuh Min Chen (Taiwan,…

From  Kelda Tan on November 2nd, 2020 0 likes 138 plays 0